Literature DB >> 27143151

Indirect and competitive enzyme-linked immunosorbent assays for monitoring the humoral response against human VEGF.

Javier Sánchez Ramírez1, Yanelys Morera Díaz1, Alexis Musacchio Lasa2, Mónica Bequet-Romero1, Yasmiana Muñoz Pozo1, Lincidio Pérez Sánchez1, Francisco Hernández-Bernal3, Osmany Mendoza Fuentes4, Katty-Hind Selman-Housein5, Jorge Víctor Gavilondo Cowley1, Marta Ayala Avila1.   

Abstract

CIGB-247, a VEGF-based vaccine, was studied in a clinical trial. This advance demands the refinement of the methodologies for assessment of vaccine immune responses. This study aimed to improve the performance of ELISAs for detecting IgG antibodies against human VEGF and the blocking activity of the serum to inhibit the VEGF/VEGFR2 interaction. The best experimental conditions were established through the evaluation of several blocking buffers, immobilization surfaces, and plate suppliers using human sera as test samples. As a result, two controlled ELISAs were used in testing of elicited immune response against VEGF in patients immunized with CIGB-247.

Entities:  

Keywords:  CIGB-247; VEGF; VEGFR2; competitive ELISA; humoral response; indirect ELISA

Mesh：

Substances：

Year:  2016        PMID： 27143151     DOI： 10.1080/15321819.2016.1184164

Source DB:  PubMed          Journal:  J Immunoassay Immunochem        ISSN： 1532-1819


  3 in total

1.  Characteristics of the specific humoral response in patients with advanced solid tumors after active immunotherapy with a VEGF vaccine, at different antigen doses and using two distinct adjuvants.

Authors:  Javier Sánchez Ramírez; Yanelys Morera Díaz; Mónica Bequet-Romero; Francisco Hernández-Bernal; Katty-Hind Selman-Housein Bernal; Ana de la Torre Santos; Eduardo Rafael Santiesteban Álvarez; Yenima Martín Bauta; Cimara H Bermúdez Badell; Josué de la Torre Pupo; Jorge V Gavilondo; Marta Ayala Avila
Journal:  BMC Immunol       Date:  2017-07-26       Impact factor: 3.615

2.  Evaluation of methodologies to determine the effect of specific active immunotherapy on VEGF levels in phase I clinical trial patients with advanced solid tumors.

Authors:  Javier Sánchez Ramírez; Mónica Bequet-Romero; Yanelys Morera Díaz; Francisco Hernández-Bernal; Ana de la Torre Santos; Katty-Hind Selman-Housein Bernal; Yenima Martín Bauta; Cimara H Bermúdez Badell; Miladys Limonta Fernández; Marta Ayala Avila
Journal:  Heliyon       Date:  2018-11-02

3.  Specific humoral response in cancer patients treated with a VEGF-specific active immunotherapy procedure within a compassionate use program.

Authors:  Javier Sánchez Ramírez; Yanelys Morera Díaz; Mónica Bequet-Romero; Francisco Hernández-Bernal; Yenima Martín Bauta; Katty-Hind Selman-Housein Bernal; Ana Victoria de la Torre Santos; Mariela Pérez de la Iglesia; Lian Trimiño Lorenzo; Marta Ayala Avila
Journal:  BMC Immunol       Date:  2020-03-14       Impact factor: 3.615
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.